News Headlines Article

Gilead seeks FDA approval of HIV-fighting drug
San Francisco Business Times

Gilead Sciences Inc. is looking to add to its HIV-fighting arsenal, seeking approval Wednesday for one of the four ingredients in its once-a-day Quad pill. Foster City-based Gilead (NASDAQ: GILD) filed a new drug application Wednesday with the Food and Drug Administration to market elvitegravir to people with the AIDS virus who have used other treatments.